Skip to main content

Fagron reports 16% increase in revenue to € 156.4 million

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 14 April 2022 – 7.00 AM CET

Fagron reports 16% increase in revenue to € 156.4 million

Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2022.

Highlights

  • Strong top line growth despite challenging operating environment
    • Revenue increased by 16.0% to € 156.4 million (10.2% at constant exchange rates), with growth across all regions
    • Organic growth of 13.3% (7.6% at constant exchange rates)
  • Navigating ongoing supply chain disruptions and risks
    • Lingering pressure on supply chain due to COVID related issues with limited direct impact from Ukraine crisis thus far
    • Inventory management and cost efficiency key focus areas to maximize product availability with centralized procurement team
  • Continued rollout of disciplined acquisition strategy
    • Acquisition of Hiperscan in Germany and Curaphar in the Netherlands further strengthens position in key markets
    • Letco acquisition and simultaneous divestment of 80% of contract manufacturing division in North America
    • Pharma-Pack acquisition in Belgium
  • Further progress on environmental and social initiatives
    • Installed 1,000 solar panels
    • Launched the global female Fagron mentoring program
  • Reporting on Compounding Services and Premium Pharmaceuticals consolidated

Rafael Padilla, CEO of Fagron:

“We have delivered robust results in the first quarter of 2022 through organic growth and M&A activities even though we are in the midst of an unpredictable operating environment given the lingering impact from COVID, ongoing supply chain challenges as well as rising inflation.

In line with our disciplined acquisition strategy, we completed three acquisitions in the first quarter of this year with a view to solidifying our position in key European markets. We also strengthened our position in North America with the acquisition of Letco, the integration of which is progressing as planned. We remain committed to further consolidating the market and adding capabilities to Fagron through a rigorous assessment of market opportunities.

Supported by the favorable underlying secular trends from increased personalization and healthcare focus globally, we remain committed to our strategic priorities and feel confident in our ability to deliver to our mid-term targets, despite the current challenging environment.”

Please open the link below for the press release:

Fagron reports 16% increase in revenue to € 156.4 million

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.